Skip to main content

Table 2 Univariate analysis of clinical factors and GPS for overall survival (n = 402)

From: Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer

  Patients (%) mOS months (95% CI) P-value
Age
<60 203 (50.5) 11.6 (10.1-13.2) 0.808
≥ 60 199 (49.5) 12.0 (9.9-14.1)  
Gender
Male 293 (72.9) 11.7 (10.1-13.3) 0.952
Female 109 (27.1) 12.1 (10.6-13.6)  
Liver Mets
Yes 125 (31.1) 11.4 (8.5-14.3) 0.352
No 277 (68.9) 12.0 (10.7-13.3)  
Peritoneal Mets
Yes 159 (39.6) 9.9 (8.4-11.5) 0.023
No 243 (60.4) 13.0 (11.2-14.8)  
Bone Mets
Yes 28 (7.0) 8.2 (7.1-9.3) 0.117
No 374 (93.0) 12.1 (10.9-13.2)  
Albumin
<3.5 77 (19.2) 7.7 (5.9-9.5) 0.001
≥ 3.5 325 (80.8) 12.4 (10.7-14.2)  
CRP
≤ 1 262 (64.9) 14.8 (12.7-17.0) 0.001
>1 140 (34.8) 8.7 (7.3-10.2)  
ECOG PS
0-1 329 (81.8) 12.4 (10.9-13.8) 0.003
≥ 2 73 (48.2) 8.7 (7.3-10.0)  
GPS
0 238 (59.2) 15.3 (13.1-17.5) 0.001
1 111 (27.6) 8.9 (7.2-10.7)  
2 53 (13.2) 7.6 (4.9-10.2)  
  1. mOS: median overall survival, Mets: metastasis, CRP: C-reactive protein, ECOG PS: Eastern Cooperative Oncology Group, performance status, GPS: Glascow prognostic score